Cargando…

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab

Introduction: [(227)Th]Th-3,2-HOPO-MSLN-mAb, a mesothelin (MSLN)-targeted thorium-227 therapeutic conjugate, is currently in phase I clinical trial; however, direct PET imaging using this conjugate is technically challenging. Thus, using the same MSLN antibody, we synthesized 3,2-HOPO and deferoxami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roy, Jyoti, Jagoda, Elaine M., Basuli, Falguni, Vasalatiy, Olga, Phelps, Tim E., Wong, Karen, Ton, Anita T., Hagemann, Urs B., Cuthbertson, Alan S., Cole, Patricia E., Hassan, Raffit, Choyke, Peter L., Lin, Frank I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161658/ https://www.ncbi.nlm.nih.gov/pubmed/34014767 http://dx.doi.org/10.1089/cbr.2020.4492

Ejemplares similares

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab
por: Jagoda, Elaine M., et al.
Publicado: (2019)

Recent Advances in Zirconium-89 Chelator Development
por: Bhatt, Nikunj B., et al.
Publicado: (2018)

The Race for Hydroxamate-Based Zirconium-89 Chelators
por: Feiner, Irene V. J., et al.
Publicado: (2021)

Alternative Chelator for (89)Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)
por: Deri, Melissa A., et al.
Publicado: (2014)

Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89
por: Bhatt, Nikunj B., et al.
Publicado: (2017)

Evaluation of (89)Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET
por: Radaram, Bhasker, et al.
Publicado: (2023)

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator
por: Alnahwi, Aiman H., et al.
Publicado: (2020)

Automated Synthesis of Fluorine-18 Labeled CXCR4 Ligand via the Conjugation with Nicotinic Acid N-Hydroxysuccinimide Ester (6-[(18)F]SFPy)
por: Basuli, Falguni, et al.
Publicado: (2020)

Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake
por: Basuli, Falguni, et al.
Publicado: (2022)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles
por: Chen, Feng, et al.
Publicado: (2015)

Model-Based Optimisation of Deferoxamine Chelation Therapy
por: Bellanti, Francesco, et al.
Publicado: (2015)

Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89
por: Zhai, Chuangyan, et al.
Publicado: (2019)

The iron chelator deferoxamine decreases myeloma cell survival
por: Yang, Feifei, et al.
Publicado: (2021)

Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
por: Leung, Nelson, et al.
Publicado: (2009)

Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator
por: Bellotti, Denise, et al.
Publicado: (2021)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice
por: N.Tinianow, Jeff, et al.
Publicado: (2016)

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
por: Perk, Lars R., et al.
Publicado: (2009)

Chelating the valley of death: Deferoxamine’s path from bench to wound clinic
por: Parker, Jennifer B., et al.
Publicado: (2023)

Fluorine-18 Labeled Fluorofuranylnorprogesterone ([(18)F]FFNP) and Dihydrotestosterone ([(18)F]FDHT) Prepared by “Fluorination on Sep-Pak” Method
por: Basuli, Falguni, et al.
Publicado: (2019)

Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine
por: Komoto, Kana, et al.
Publicado: (2020)

Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability
por: Kang, Chi Soo, et al.
Publicado: (2022)

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
por: Quanz, Maria, et al.
Publicado: (2018)

In Vitro and In Vivo Characterization of (89)Zirconium-Labeled Lintuzumab Molecule
por: Allen, Kevin J. H., et al.
Publicado: (2022)

Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction
por: Ikeda, Yasumasa, et al.
Publicado: (2014)

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)
por: Lazaridou, Maria, et al.
Publicado: (2020)

Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats
por: Feng, Yunfei, et al.
Publicado: (2023)

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
por: Hassan, Raffit, et al.
Publicado: (2020)

Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease
por: Laban, Kamil G., et al.
Publicado: (2019)

Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
por: de Keizer, Bart, et al.
Publicado: (2019)

Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation
por: Mostafa, Ahmed M. A., et al.
Publicado: (2023)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Competitive blocking of salivary gland [(18)F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
por: Roy, Jyoti, et al.
Publicado: (2021)

Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development
por: Pandya, Darpan N., et al.
Publicado: (2017)

Optimization of the Sensitization Process and Stability of Octadentate Eu(III) 1,2-HOPO Complexes
por: D’Aléo, Anthony, et al.
Publicado: (2015)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
por: van de Watering, Floor C. J., et al.
Publicado: (2014)

The effect of process variables on the physical properties and microstructure of HOPO nanoemulsion flakes obtained by refractance window
por: Hernández-Carrión, M., et al.
Publicado: (2021)

Comparison Between Hesperidin, Coumarin, and Deferoxamine Iron Chelation and Antioxidant Activity Against Excessive Iron in the Iron Overloaded Mice
por: Aalikhani, Mahdi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ubm7r04vb4l4epn6lv2m5il7ro